TP53
Clinical trials for TP53 explained in plain language.
Never miss a new study
Get alerted when new TP53 trials appear
Sign up with your email to follow new studies for TP53, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a Two-Drug combo outsmart a deadly leukemia?
⭐️ CURE ⭐️ Recruiting nowThis trial is testing whether adding bortezomib to standard chemotherapy (CPX-351) can improve outcomes for people with a newly diagnosed, aggressive form of acute myeloid leukemia that has a TP53 mutation. The study aims to find a safe dose and see if the combination leads to mo…
Matched conditions: TP53
Phase: PHASE1, PHASE2 • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: ⭐️ CURE ⭐️
Last updated Jul 24, 2026 00:00 UTC
-
New stem cell transplant aims to cut dangerous side effects in blood cancer patients
Disease control Recruiting nowThis study tests a special stem cell transplant for children and adults with blood cancers like leukemia. The transplant uses stem cells that have had certain immune cells removed to lower the risk of graft-versus-host disease, a serious complication. About 70 participants will r…
Matched conditions: TP53
Phase: PHASE2 • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New drug combo aims to stall endometrial cancer in High-Risk patients
Disease control Recruiting nowThis study tests whether two drugs, abemaciclib and letrozole, can help keep advanced or recurrent endometrial cancer from getting worse. About 32 people with a specific type of estrogen-sensitive cancer will take these pills daily after initial treatment. The goal is to see if t…
Matched conditions: TP53
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Promising cocktail targets deadly lymphoma mutation
Disease control Recruiting nowThis phase 2 trial tests a combination of three drugs—glofitamab, a PD-1 inhibitor, and lenalidomide—in 24 adults with relapsed or refractory large B-cell lymphoma that has a TP53 gene mutation. The goal is to see if this mix can shrink tumors or make them disappear. The study is…
Matched conditions: TP53
Phase: PHASE2 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC